The list of the 15 most profitable pharmaceutical companies in 2016 was announced on August 10. However, the industry has found some "unsatisfactory" places, compared with the revelry on the list. According to the latest research report, the pace of the 15 companies has slowed markedly compared to last year, with a year-on-year growth rate of 4 per cent. Among them, novartis, sanofi, gilead and astrazeneca have seen a decline in performance, unavoidably, this is a tough 2016.
Clearly, the "flatness" of the growth curve has led many employees to worry directly about their own pockets and jobs. EP Vantage, which counts data from the annual report of 11 pharmaceutical giants, found that by the end of 2016, the number of employees at these companies was 866,179, with a 1% contraction overall.
Worst loss: sanofi
The total number of employees fell by 8%, from 115,631 at the start of the year to 106,859 at the end of the year. The 2016 wave of layoffs is well deserved to be led by sanofi.
The primary cause of this devastation is the price pressures under the control of medical costs and the impact of biosimilars. Some analysts believe that the pressure of spending has been on the horizon as a result of the continuing downturn in diabetes performance. Eli lilly and boehringer ingerheim took the biosimilars of Lantus, which gave sanofi a crucial blow. In the end, sanofi kicked off the 2016 campaign by cutting 500 jobs in France. Since then, its U.S. sales of diabetes drugs and cardiovascular drugs have been cut by 20 percent.
Most surprising increase: alberi
Despite the scale of the other pharmaceutical giants, which are only in the middle and lower reaches of the market, alberi's staff has given us a small surprise. In 2016, it added 2, 000 employees, up to 30, 000 at the end of the year, outpacing the older group, roche (3%) and eli lilly (2%).
Hand who repair the merlot, focus on antiviral, neurology, immunology, oncology, kidney disease, such as women's health in the field of new drug research and development, abbvie "somersaults cloud" turn has its internal logic.
The clouds open to the moon: lilly
Eli lilly is one of only three expansion companies. Its number of employees increased by 2% in 2016 to 41,975.
In fact, the 2 percent figure is very impressive. In recent years, with the patent protection of blockbuster products such as tumor drug Gemzar, psychotropic drug Zyprexa, depression drug Cymbalta and osteoporosis drug Evista, it has experienced a period of pain. To add insult to injury, last year, the semagacestat, which was seen as a future star for the treatment of alzheimer's, was forced to pay again with big job cuts.
Now, the company has turned a profit, making the Numbers look better.
In addition, astrazeneca, Pfizer, glaxosmithkline and Johnson & Johnson are among the layoffs, fine-tuning their workforce.
